Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-03-22
2010-12-14
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C435S377000, C435S320100, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07851452
ABSTRACT:
This invention provides methods of inducing apoptosis in a bcl-6-expressing cell and methods of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising administration of a composition that reduces the amount of the bcl-6 protein or of an mRNA molecule encoding same, a composition comprising a nucleic acid molecule complementary to or corresponding to a region of the mRNA molecule, or a vector expressing the nucleic acid molecule. In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence corresponding to or complementary to accessible regions of bcl-6 mRNA, and vectors, cells, compositions, and kits comprising same.
REFERENCES:
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 6140125 (2000-10-01), Taylor et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 2002/0114784 (2002-08-01), Li et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
Opalinska et al., Blood vol. 102(11):137A-138A, 2003.
Artiga MJ et al. “A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas,” Am J Pathol. Apr. 2002; 160(4): 1371-80.
Baron BW et al. “Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;g32) and t(3:22)(g27;q11) in B-cell lymphomas,” Proc Natl Acad Sci U S A Jun. 1, 1993;90(11):5262-6.
Barrans SL et al. “Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.” Br J Haematol May 2002,117(2):322-32.
Braaten KM et al. “BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.” Clin Cancer Res. Mar. 2003;9(3):1063-9.
Brindle KM, Br. J. Radiol. 76 Spec., No. 2:S111-7, 2003.
Buchwald et al., Surgery 88:507, 1980.
Caudy AA et al., Gene & Devel, 16:2491-96.
Chang CC et al, “BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor” PNAS 93(14): 6947-52, 1996.
Chang CC et al. “Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.” Arch Pathol Lab Med. Feb. 2003;127(2):208-12.
Goodson, Medical Applications of Controlled Release, Supra, vol. 2, pp. 115-138, 1984.
Gifford et al., “Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching, fluorescent reporter molecules”, Nucleic Acids Research; 2005, vol. 33, No. 3, 9 Pages.
Harris NL et al. “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group,” Blood. Sep. 1, 1994;84(5):1361-92.
Jerkeman M et al. “Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study.” Int J Oncol. Jan. 2002;20(1):161-5.
Kawasaki C et al. “Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas.” Leuk Lymphoma. Sep.-Oct. 2001;42(5):1099-106.
Lossos IS et al. “Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.” Blood. Aug. 15, 2001;98(4):945-51.
Lahorte CM et al., Eur. J. Nucl. Med. Mol. Imaging 31(6)887-919, 2004.
Langer, Science, 249:1527-1533, 1990.
Kalota A, “Design of antisense oligonucleotides and short interfering RNA duplexes (siRNA) targeted to BCL6 mRNA: towards rational drug development for specific lymphoma subsets”. JB. Blood Cells Mol Dis. May-Jun. 2007;38(3):199-203. Epub Jan. 24, 2007.
Opalinska et al., “Oxetance modified, Conformationaliy Constrained, antisense Oligodeoxyribounucleotides function efficiently as gene silencing molecules”, Nucleic Acids Research, 2004, vol. 32. No. 19, 5791-5799.
Sánchez-Beato M et al. “Cell cycle dereoulation in B-cell lymphomas.” Blood. Feb. 15, 2003;101(4)1220-35. Epub Sep. 12, 2002.
Saudek et al., N. Engl. J. Med. 321:574.1989.
Sefton, CRC Crit. Ref. Biomed. Eng. 14:201, 1987.
Shaffer AL et al. “BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.” Immunity. Aug. 13, 2000(2)199-212.
Sokol et al., “Real time detection of DNA-RNA hybridization in Living Cells”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 11538-11543, Sep. 1998.
Tang TT et al. “The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor.” J Biol Chem. Apr. 19, 2002;277(16)14255-65. Epub Jan. 2, 2002.
Ueda C et al. “Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications.” Leuk Lymphoma. Jul. 2002;43(7):1375-81.
Vitolo U et al. “Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.” Leukemia. Feb. 2002;16(2):268-75.
Ye BH et al. “Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B-cell lymphoma.” EMBO J. Dec. 15, 1995;14(24):6209-17.
Ye BH et al, “The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.” Nat Genet. Jun. 1997;16(2)161-70.
International Search Report of Application No. PCT/US05/09349 dated Aug. 16, 2006.
Cohen Mark S.
McGarry Sean R
Pearl Cohen Zedek Latzer LLP
The Trustees of the University of Pennsylvania
LandOfFree
Methods of use of bcl-6-derived nucleotides to induce apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use of bcl-6-derived nucleotides to induce apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use of bcl-6-derived nucleotides to induce apoptosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173540